Propelled by the positive results of the limited commercial release of its second proprietary product line, Nextremity Solutions, Inc. announces the full launch of the Re+Line Bunion Correction System in the United States.
Nextremity Solutions Launches Re+Line Bunion System
1 min read Premium comments
Secondary
Rod K. Mayer, company president and CEO, commented in the April 29, 2014 news release, “We are very pleased by the overwhelmingly favorable surgeon feedback on the versatility and stable fixation characteristics of Re+Line. This is important to us given the multiple techniques utilized by forefoot surgeons in bunion correction surgery today. Consequently, we anticipate that Re+Line’s unique, low-profile, tension-band plate design will to continue to expand in its applications as we gain more market experience.”
William von Brendel, EVP Global Marketing and International Sales of Nextremity Solutions, remarked, “The combination of Nextra and Re+Line provides us a highly differentiated product presence in the two largest and fastest growing forefoot surgery segments. Additionally, the high rates of combined hammertoe and bunion surgery will provide important synergy to our growing best-in-class product portfolio.”
Rod K. Mayer told OTW, “It is our goal that one year from now, the Re+Line Bunion Correction System will be recognized as a unique solution for bunion surgery. The Re+Line plate’s unique, low-profile 4-point fixation was designed to provide superior stability with multiple osteotomy techniques. This is what forefoot surgeons require to achieve an excellent and enduring surgical outcome with minimum patient downtime. Re+Line will take its place side-by-side with the Nextra Hammertoe Correction System as industry leading implant systems in the hi-growth forefoot surgery market.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.